Novartis Prevails In Patent Suit Vs. Dr. Reddy's Over Lamisil
Dr. Reddy's Laboratories withdrew its challenge to the Lamisil patent and conceded that it is valid, enforceable and had been infringed by the Indian generic maker, Novartis said Friday.
Dr. Reddy's said it pulled its legal challenge “because the time needed to obtain a favorable Federal Circuit decision prior to patent expiration would not be met.”
Novartis filed the lawsuit the U.S. District...
To view the full article, register now.